Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Evaluation of the immunomodulatory activity of meloxicam <i>in vitro</i> and <i>in vivo</i>
Abstract
Purpose: To demonstrate the immunomodulatory activity of meloxicam based on cellular and humoral immune responses and in mice.
Methods: Cyclophosphamide-induced neutropenia assay and delayed-type hypersensitivity assay (DTH) were carried out to assess cellular immunity. In addition, mouse lethality and haemagglutination assays were carried out to investigate humoral immunity. Meloxicam was administered intraperitoneally in two doses, i.e., 5 mg/kg and 10 mg/kg to mice.
Results: Cyclophosphamide-induced neutropenia assay data showed a significant decline in differential leukocyte count (DLC) and total leukocytes count (TLC) in the meloxicam administered groups when compared with control group (p < 0.05). In DTH test, meloxicam showed a significant reduction in skin thickness against dinitrochlorobenzene than the control group, respectively (p < 0.05). A significant dose-dependent decline in antibody titre in the meloxicam-treated groups was observed (p < 0.05), while a gradual decrease in antibody titre occurred with increasing dose. However, there was significant rise in mortality ratio with increasing dose of meloxicam (p < 0.05). Conclusion: The results indicate that meloxicam has immunosuppressive activity in mice, and therefore, can potentially be developed for use in countering organ transplant rejection.
